(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Track down Your Optimal Conservative Vehicle: Famous Brands to Consider - 2Scientists document a death from a meat allergy tied to certain ticks
- 3What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- 4The Main 20 Photography Instagram Records to Follow
- 5Senior's Manual for Obtaining a Hyundai Ioniq EV: Tips
- Russia downs 16 drones heading for Moscow, mayor says
- Banks for High Fixed Store Rates: Augment Your Investment funds
- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
- See as Your #1: These Low-Sugar Food sources You Ought to Attempt
- Vote In favor of Your Number one Savvy Beds
- Why is the Artemis 2 rocket launch different from all other rocket launches?
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- It's time for Artemis II to break Apollo 13's distance record. What to know about the moon flyby
- Blue Origin's next space tourism flight will break new ground for people with disabilities
